Abstract:<p>The incidence of hematological malignancies such as multiple myeloma, leukemia, and lymphoma has increased over time. Although bone marrow transplantation, immunotherapy and chemotherapy have led to significant improvements in efficacy, poor prognosis in elderly patients, recurrence and high mortality among hematological malignancies remain major challenges, and innovative therapeutic strategies should be explored. Besides directly lyse tumor cells, oncolytic viruses can activate immune responses or be engineered to express therapeutic factors to increase antitumor efficacy, and have gradually been recognized as an appealing approach for fighting cancers. An increasing number of studies have applied oncolytic viruses in hematological malignancies and made progress. In particular, strategies combining immunotherapy and oncolytic virotherapy are emerging. Various phase I clinical trials of oncolytic reovirus with lenalidomide or programmed death 1(PD-1) immune checkpoint inhibitors in multiple myeloma are ongoing. Moreover, preclinical studies of combinations with chimeric antigen receptor T (CAR-T) cells are underway. Thus, oncolytic virotherapy is expected to be a promising approach to cure hematological malignancies. This review summarizes progress in oncolytic virus research in hematological malignancies. After briefly reviewing the development and oncolytic mechanism of oncolytic viruses, we focus on delivery methods of oncolytic viruses, especially systemic delivery that is suitable for hematological tumors. We then discuss the main types of oncolytic viruses applied for hematological malignancies and related clinical trials. In addition, we present several ways to improve the antitumor efficacy of oncolytic viruses. Finally, we discuss current challenges and provide suggestions for future studies.</p>

[Advances in combination strategies with oncolytic virotherapy].

The combination therapy of oncolytic virotherapy

Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic

Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

Recent advances in targeting cancer stem cells using oncolytic viruses

Current Landscape and Perspective of Oncolytic Viruses and Their Combination Therapies.

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Oncolytic Viruses in Cancer Immunotherapy

The investigation of oncolytic viruses in the field of cancer therapy

Recent progress in combination therapy of oncolytic vaccinia virus

Oncolytic viruses as a promising therapeutic strategy for hematological malignancies

Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer

Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Oncolytic virotherapy: basic principles, recent advances and future directions

Enhancing Cancer Immunotherapy: A Novel Approach through the Integration of Oncolytic Virotherapy with CAR-T and NK Cell Therapies

Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer